The central role of GATA-3 in the underlying immune pathways for the development of inflammatory allergic responses, and its significantly increased expression in the airways of asthma patients [120,121,122,123], support GATA-3 as a novel target for therapeutic intervention in type-2-driven asthma (Figure 1). Here, GATA3 is linked to asthma.